Abilify delivers but patent cliff looms for Otsuka
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical's mainstay product, the atypical antipsychotic Abilify (aripiprazole), has again put in a strong performance but will leave a large revenue hole after US exclusivity expires next year.